Kiora Pharmaceuticals (KPRX) Other Non-Current Liabilities (2014 - 2026)

Kiora Pharmaceuticals (KPRX) has 12 years of Other Non-Current Liabilities data on file, last reported at $2.9 million in Q1 2026.

• Quarterly Other Non-Current Liabilities fell 34.03% year-over-year to $2.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.9 million (down 34.03% YoY) and the FY2025 annual result came in at $2.9 million, down 29.87% from the prior year.
• Other Non-Current Liabilities was little changed at $2.9 million in Q1 2026, from $2.9 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $18.8 million in Q2 2022 to a low of $2.9 million in Q4 2025.
• A 5-year average of $8.0 million and a median of $4.5 million in 2025 frame the typical range for Other Non-Current Liabilities.
• Annual changes were most pronounced in 2022 — Other Non-Current Liabilities surged 879.4% — and 2026, when it plunged 34.03%.
• Tracing KPRX's Other Non-Current Liabilities over 5 years: stood at $3.3 million in 2022, then soared by 54.99% to $5.1 million in 2023, then dropped by 18.28% to $4.2 million in 2024, then dropped by 29.87% to $2.9 million in 2025, then gained by 0.25% to $2.9 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $2.9 million (Q1 2026), $2.9 million (Q4 2025), and $16.6 million (Q3 2025), per Business Quant data.